Liquidia (NASDAQ:LQDA) Stock: Insider Roger Jeffs Sells 32,744 Shares

Posted by Brian Himes on Oct 15th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) CEO Roger Jeffs sold 32,744 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $932,549.12. Following the transaction, the chief executive officer owned 1,125,848 shares of the company’s stock, valued at approximately $32,064,151.04. This trade represents a 2.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Up 26.6%

LQDA opened at $33.94 on Thursday. The business has a 50 day moving average of $62.30 and a 200-day moving average of $61.74. The stock has a market capitalization of $3.04 billion, a price-to-earnings ratio of 24.77 and a beta of 0.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. Liquidia Corporation has a 1-year low of $21.94 and a 1-year high of $93.61.

Liquidia (NASDAQ:LQDA – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The company had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company’s revenue was up 1842.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.49) EPS. As a group, sell-side analysts anticipate that Liquidia Corporation will post 2.05 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its stake in Liquidia by 63.3% during the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock worth $2,199,000 after purchasing an additional 22,592 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Liquidia in the 2nd quarter valued at approximately $29,694,000. Seven Fleet Capital Management LP grew its stake in shares of Liquidia by 25.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after purchasing an additional 51,727 shares during the period. Bank of America Corp DE raised its holdings in shares of Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares in the last quarter. Finally, Handelsbanken Fonder AB acquired a new position in shares of Liquidia in the 2nd quarter worth approximately $1,993,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

Positive Sentiment: The settlement allows Liquidia to continue commercializing YUTREPIA for pulmonary arterial hypertension (PAH) without interruption, removing a major source of legal and commercial uncertainty. Liquidia settlement announcement
Positive Sentiment: Preliminary third-quarter YUTREPIA sales reached $222.7 million, contributing to $396.1 million in cash and equivalents. Management said it expects ongoing sales and existing cash to fund settlement obligations and clinical programs without additional financing. RTTNews settlement report
Positive Sentiment: Analyst sentiment improved following the agreement. BTIG upgraded LQDA from “neutral” to “buy” with a $70 price target, while Lifesci Capital raised its rating to “outperform” and set a $59 target. Needham maintained “buy” but lowered its target to $58.
Positive Sentiment: Trading activity reflected strong investor interest, with call-option volume more than doubling its average level.
Neutral Sentiment: Liquidia agreed to pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to the antitrust litigation. The payments resolve the disputes but will significantly draw down cash.
Negative Sentiment: The company will not appeal the patent ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing potential revenue opportunities. Zacks settlement analysis
Negative Sentiment: Multiple executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. Because the sales were planned and left executives with substantial holdings, they are a limited standalone signal, but broader insider activity remains heavily weighted toward selling.

Analysts Set New Price Targets

Several research firms have recently issued reports on LQDA. Bank of America boosted their price objective on shares of Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Citigroup reaffirmed a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. Weiss Ratings upgraded shares of Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Wall Street Zen downgraded Liquidia from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Finally, Needham & Company LLC decreased their target price on Liquidia from $72.00 to $58.00 and set a “buy” rating on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $77.31.

Read Our Latest Report on LQDA

Liquidia Company Profile

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).